BIO, QLS Advisors, and Informa Pharma Intelligence have released a new report on clinical development success rates covering 2011-2020
The report includes comparisons of success rates across indications and modalities, regulatory factors, and predictive factors driving successes and failures in drug development. This new data will help shape risk profiles and valuation metrics across investment and pharma R&D portfolios. Access it here.
Informa Pharma Intelligence and QLS Advisors Partner to Pilot Predictive Analysis Tool for Clinical Trials
Partnership will help inform key decisions with new drug-level probability of approval scores powered by QLS and incorporated into Informa Pharma Intelligence’s Biomedtracker